Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockGuruFocus · 3 days ago
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockBusiness Wire · 3 days ago
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmPRNewsWire · 3 days ago
Arcus Biosciences Announces Commencement of Public Offering of Common StockBusiness Wire · 3 days ago
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still AheadSeeking Alpha · 4 days ago
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor DayMarketBeat · 4 days agoArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.89 | -$0.72 | Beat |
| May 5, 2026 | -$0.92 | -$1.02 | Miss |
| Feb 25, 2026 | -$1.11 | -$0.89 | Beat |
| Oct 28, 2025 | -$1.33 | -$1.27 | Beat |
| Aug 6, 2025 | -$1.14 | -$0.08 | Beat |
| May 6, 2025 | -$1.02 | -$1.14 | Miss |